Diana Brainard
CIK 1818070 · Chief Executive Officer · last filed 2026-09-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALVR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
139 MAIN STREET, SUITE 500
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NKTR | Director | 3,904 | $38.65 | $150.9K | $0 | 5 | 2026-09-25 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Chief Executive Officer | 31,451 | $9.81 | $308.5K | -$569.2K | 38 | 2024-11-20 |
Recent Filings · Page 2 of 8
72 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-08-22 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −5,390 | -$4.0K | EDGAR |
| 2024-08-21 | KLRS | Notice (144) | −5,390 | -$4.0K | EDGAR |
| 2024-08-20 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −3,091 | -$2.3K | EDGAR |
| 2024-08-19 | KLRS | Notice (144) | −3,091 | -$2.3K | EDGAR |
| 2024-08-07 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −10,847 | -$8.0K | EDGAR |
| 2024-08-06 | KLRS | Notice (144) | −10,847 | -$8.0K | EDGAR |
| 2024-07-23 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −9,731 | -$7.3K | EDGAR |
| 2024-07-19 | KLRS | Notice (144) | −9,731 | -$7.3K | EDGAR |
| 2024-07-03 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −1,489 | -$1.1K | EDGAR |
| 2024-07-02 | KLRS | Notice (144) | −1,489 | -$1.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.